1Tabaton M, Nunzi MG, Xue R, et al. Soluble amyloid beta - protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun, 1994, 200 (3) : 1598 -1603.
2Lewezuk P, Esselmann H, Otto M, et al. Neumchemical diagnosis of Alzheimer' s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau Neurobiol Aging, 2004, 25 (3) : 273 -281.
3Blennow K, Vanmechelen E, Hampel H, et al. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol, 2001, 24 ( 1 - 3 ) :87 - 97.
4Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E * 4 al- lele effects on cerebrospinal fluid beta - amyloid 42 in adults with norreal cognition. Arch Neurol, 2006, 63(7) : 936 -939.
5Alessandro S, Alessandro M, Sergio B, et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci, 2006, 251 ( 1 - 2) : 124 - 128.
6John SK, Kauwe SJ, Sumi C, et al. Extreme cerebrospinal fluid amyloidβlevels identify family with late - onset Alzheimer' s disease presenilin 1 mutation. Ann Neurol, 2007, 61 (5) : 446 - 453.
7Andersson C, Blennowb K, Almkvist O, et al. Increasing CSF phospho - tau levels during cognitive decline and progression to dementia. Neurobiol Aging, 2008, 29(10) :1466 - 1473.
8Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord, 2006, 20(1) : 6-15.
9Maccioni RB, Lavados M, Guillon M, et al. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging, 2006, 27 ( 2 ) : 237 - 244.
10Franz G, Beer R, Kampfl A, et al. Amyloid beta 1 - 42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology, 2003, 60(9) :1457 - 1461.
2[1]American Psychiatric Association,ed.Diagnostic and statistical manual of mental disorders.4 th ed.Washington:American Psychiatric Association,1994.141-146.
3[2]Galasko D.Biological markers and the treatment of Alzheimer's disease.J Mol Neurosci,2001,17:119-125.
4[3]Galasko D.CSF tau and Abeta 42:logical biomarkers for Alzheimer's disease? Neurobiol Aging,1998,19:117-119.
5[4]Andreasen N,Blennow K.CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.Clin Neurol Neurosurg,2005,107:165-173.
6[5]Andreasen N,Hesse C,Davidsson P,et al.Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease:differences between early-and late-onset Alzheimer disease and stability during the course of disease.Arch Neurol,1999,56:673-680.
7[6]Clark CM,Xie S,Chittams J,et al.Cerebrospinal fluid tau and beta-amyloid:how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol,2003,60:1696-1702.
8[8]Andreasen N,Sjogren M,Blennow K.CSF markers for Alzheimer's disease:total tau,phospho-tau and Abeta 42.World J Biol Psychiatry,2003,4:147-155.
9[9]Andreasen N,Vanmechelen E,Vanderstichele H,et al.Cerebrospinal fluid levels of total-tau,phospho-tau and Abeta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.Acta Neurol Scand Suppl,2003,179:47-51.
10[10]Blennow K,Vanmechelen E,Hampel H.CSF total tau,Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.Mol Neurobiol,2001,24:87-97.
9Macin D? Tomasz D,Witold G. The role of MRI and spiralCT with 3D renconstruction techniques in the temperalbone tumor surgical treatment[J]. Int Con Series ? 2003 ,1240:1443 - 1448.
10Ropireddy D, Bachus S,Ascoli G. Non-homogeneousstereological properties of the rat hippocampus from high-resolution 3D serial reconstruction of thin histologicalsections[J]. Neuroscience ^2012,205 :91 — 111.
